Our Core Technology Platform Published in the Journal of the Chinese Chemical Society
T-E Pharma is honored to be invited by the Journal of the Chinese Chemical Society (JCCS) to publish a review […]
Scientific Publication
News
T-E Pharma Launches Pre-IPO Capital Raise Pursuing a Dual-Engine Strategy in Metabolic and Oncology Therapeutics; Targeting TPEx Emerging Stock Board Listing in Q4 2026
T-E Pharma has officially launched its pre-initial public offering (pre-IPO) fundraising program. The proceeds will be used to accelerate the
Meeing
Join our presentation at the BIOLOGICS WORLD TAIWAN 2026
We are honored to announce that Dr. Tse-Wen Chang, Chairman of T-E Pharma, and Dr. Hsin-Mao Chu, CEO of the
Scientific Publication
Our Latest Research Published in International Journal of Pharmaceutics
Great news! The long-acting GLP-1 receptor agonist TE-8105 has achieved an innovative breakthrough in formulation development, successfully creating a more
R&D Progress
TE-6168 drug development was selected as a significant case of the Center for Drug Evaluation (CDE), Taiwan
“The development of TE-6168, the novel thrombolytic fusion protein” was selected as a significant case of the Center for Drug
News
T-E Pharma Hosts Annual Year-End Gala as Five Drug Candidates Reach Key Development Milestones
T-E Pharma held its annual year-end gala on January 29, providing an overview of the Group’s R&D achievements and future
Reported
An Interview with Chairman Tse-Wen Chang, Founder of Immunwork and T-E Meds: A Journey Through Science and Entrepreneurship
Dr. Tse-Wen Chang, Chairman and Founder of Immunwork and T-E Meds, built his scientific career through National Tsing-Hua University, Harvard
Scientific Publication
Our Latest Research Published in Haematologica
Great news! Our latest publication presents TE-1146 as a novel therapeutic strategy for the treatment of multiple myeloma. We are
Reported
Immunwork Spotlight: TE-8214 — A Long-Acting Drug Revolution from “Maltose” to “Aqueous Solution”
In 2025, Immunwork successfully reached key clinical trial milestones for two drug candidates, TE-8105 and TE-8214. In an exclusive interview
R&D Progress
Immunwork Announces Positive Phase 1/2a Results for TE-8105, a Long-Acting GLP-1 RA, Demonstrating Favorable Safety, Tolerability, and Weight-loss Potential
Immunwork, Inc., a subsidiary of T-E Pharma, today announced the successful completion of the Phase 1/2a clinical trial of its